VCYT — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-07-31

• We serve global markets with two complementary models. In the United States, we offer laboratory developed tests, or LDTs, through our centralized CLIA certified laboratories in South San Francisco and San Diego, California, supported by our cytopathology lab in Austin, Texas. Additionally, outside …

• We believe our broad menu of advanced diagnostic tests, combined with our ability to deliver them globally, differentiates us in the diagnostics industry.

• Revenue increased $20.2 million for the three months ended June 30, 2026 compared to the same period in 2025. This was primarily due to a $23.4 million increase in testing revenue, partially offset by a $3.5 million decrease in our biopharmaceutical and other revenue. The 19% growth in testing reven…

• Revenue increased $44.8 million for the six months ended June 30, 2026 compared to the same period in 2025. This was primarily due to a $51.2 million increase in testing revenue partially offset by a $6.8 million decrease in our biopharmaceutical and other revenue. The 22% growth in testing revenue …

• Product revenue increased $0.3 million and $0.4 million for the three and six months ended June 30, 2026, respectively, compared to the same periods in 2025.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• In the United States, we currently offer tests in prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). In addition, we are planning to offer our Prosigna test for breast cancer as an LDT in 2026.

• We serve global markets with two complementary models. In the United States, we offer LDTs through our centralized CLIA certified laboratories in South San Francisco and San Diego, California, supported by our cytopathology expertise in Austin, Texas. Additionally, outside of the United States, we p…

• Intangible asset amortization - cost of revenue2,707 2,585 122 5%

• Intangible asset amortization - operating expenses579 622 (43)(7)%

• Revenue increased $24.6 million for the three months ended March 31, 2026 compared to the same period in 2025. This was primarily due to a $27.8 million increase in testing revenue partially offset by a $3.3 million decrease in our biopharmaceutical and other revenue. The 26% growth in testing reven…

Text added vs the prior filing · source: 10-Q · 2026-07-31

• During the three months ended June 30, 2026, the following Section 16 officers and directors adopted, modified or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act). None of our other officers or directors adopted, modified or terminated suc…

• •Karin Eastham, Director, adopted a new trading plan on May 28, 2026 (with the first trade under the new plan scheduled for approximately August 27, 2026). The trading plan will be effective until May 7, 2027 to sell an aggregate of 23,841 shares of our common stock.

• •Muna Bhanji, Director, adopted a new trading plan on June 2, 2026 (with the first trade under the new plan scheduled for approximately September 1, 2026). The trading plan will be effective until August 31, 2027 to sell an aggregate of 3,728 shares of our common stock.

• •John Leite, Global Chief Commercial Officer, adopted a new trading plan on June 9, 2026 (with the first trade under the new plan scheduled for approximately September 8, 2026). The trading plan will be effective until August 13, 2027 to sell 100% of the net shares resulting from the vesting of 44,2…

• •Jens Holstein, Director, adopted a new trading plan on June 12, 2026 (with the first trade under the new plan scheduled for approximately September 11, 2026). The trading plan will be effective until June 7, 2027 to sell an aggregate of 20,000 shares of our common stock.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• The Board of Directors of the Company amended and restated the Company’s amended and restated bylaws (as so amended and restated, the “Bylaws”), effective May 1, 2026. The amendments implement a cure process for certain deficiencies in director nomination notices submitted by stockholders. For nomin…

• This description of the amendments to the Bylaws is not complete and is qualified in its entirety by reference to the text of the Bylaws filed as Exhibit 3.2 to this report.

• During the three months ended March 31, 2026, none of our officers and directors adopted, modified or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act).